Free Trial

Polyrizon (PLRZ) Competitors

Polyrizon logo
$1.39 -0.49 (-26.06%)
As of 04:00 PM Eastern

PLRZ vs. LGVN, CMMB, NAII, RLMD, FNCH, CING, VYNE, CYCC, AYTU, and BLRX

Should you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Longeveron (LGVN), Chemomab Therapeutics (CMMB), Natural Alternatives International (NAII), Relmada Therapeutics (RLMD), Finch Therapeutics Group (FNCH), Cingulate (CING), VYNE Therapeutics (VYNE), Cyclacel Pharmaceuticals (CYCC), Aytu BioPharma (AYTU), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry.

Polyrizon vs. Its Competitors

Polyrizon (NASDAQ:PLRZ) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Polyrizon has higher earnings, but lower revenue than Longeveron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyrizonN/AN/A-$1.54MN/AN/A
Longeveron$2.39M10.56-$15.97M-$6.28-0.27

10.0% of Longeveron shares are held by institutional investors. 11.2% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Polyrizon has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. Polyrizon's return on equity of 0.00% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
PolyrizonN/A N/A N/A
Longeveron -760.72%-85.07%-70.74%

In the previous week, Polyrizon had 1 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for Polyrizon and 2 mentions for Longeveron. Polyrizon's average media sentiment score of 0.40 beat Longeveron's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Polyrizon
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Longeveron has a consensus target price of $8.67, suggesting a potential upside of 412.82%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than Polyrizon.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Longeveron
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

Summary

Longeveron beats Polyrizon on 7 of the 13 factors compared between the two stocks.

Get Polyrizon News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLRZ vs. The Competition

MetricPolyrizonMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.41M$3.06B$5.67B$9.49B
Dividend YieldN/A2.44%4.05%4.00%
P/E RatioN/A20.8627.9419.95
Price / SalesN/A246.06396.5882.68
Price / CashN/A41.9636.1958.45
Price / Book0.008.308.635.82
Net Income-$1.54M-$55.19M$3.24B$258.42M
7 Day Performance43.36%5.07%3.22%1.94%
1 Month Performance93.06%17.61%10.72%12.02%
1 Year PerformanceN/A7.03%34.94%20.80%

Polyrizon Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLRZ
Polyrizon
N/A$1.39
-26.1%
N/AN/A$7.41MN/A0.00N/ANews Coverage
Gap Down
LGVN
Longeveron
2.799 of 5 stars
$1.46
-0.7%
$8.67
+493.6%
-40.2%$21.94M$2.23M-0.2320
CMMB
Chemomab Therapeutics
2.2041 of 5 stars
$1.14
-0.9%
$8.50
+645.6%
-10.9%$21.69MN/A-1.5020Positive News
NAII
Natural Alternatives International
0.6266 of 5 stars
$3.43
+0.3%
N/A-37.0%$21.13M$113.80M-2.47290Positive News
RLMD
Relmada Therapeutics
4.5457 of 5 stars
$0.61
-4.1%
$5.00
+724.7%
-82.0%$20.98MN/A-0.2410
FNCH
Finch Therapeutics Group
N/A$12.50
-2.0%
N/A+866.9%$20.47MN/A-1.42190
CING
Cingulate
2.5934 of 5 stars
$4.72
+4.4%
$26.00
+450.8%
+1,437.0%$20.04MN/A-0.5620
VYNE
VYNE Therapeutics
2.1933 of 5 stars
$1.26
-2.3%
$6.25
+396.0%
-30.6%$19.62M$500K-1.2730
CYCC
Cyclacel Pharmaceuticals
0.9804 of 5 stars
$8.20
-33.5%
N/A-96.5%$19.54M$40K-0.0114Gap Up
High Trading Volume
AYTU
Aytu BioPharma
3.766 of 5 stars
$2.32
+6.9%
$10.00
+331.0%
-5.4%$19.48M$81M-3.22160News Coverage
Positive News
BLRX
BioLineRx
2.0608 of 5 stars
$4.60
+1.8%
$26.00
+465.2%
-85.9%$19.27M$28.94M-0.5240

Related Companies and Tools


This page (NASDAQ:PLRZ) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners